Houston Baptist University has created a program that is training the next generation of cybersecurity professionals. Courtesy of HBU

A few years ago, Houston Baptist University realized there was a huge need for more engineering programs within Houston higher education in one area particularly: Cybersecurity.

The school brought in Stan Napper from Louisiana Tech University to become the founding dean of the College of Engineering. The college now has three bachelor's degree programs in cyber engineering, electrical engineering, and computer science.

"Cyber engineering is designing secure systems at the interface of operational technology and information technology," says Napper. "Cyber engineering is in the middle of devices and data. It's in the middle of the hardware and software. And, academically, it's in the middle of electrical engineering and computer science."

The program is the only of its kind in Texas, Napper says. In fact, he says he doesn't know of any other similar programs other than the one he was a part of at Louisiana Tech. However, he does expect that to change. There's a growing need for cybersecurity specialists — especially in the health care and energy industries.

"One of those things that really got my attention a couple of years ago is in 2017, the FDA issued a recall on the over 450,000 pacemakers that had already been implanted," Napper says. "Modern pacemakers now can be controlled remotely through the skin to change the pacing frequency or some other parameters of that pacemaker without having to go back and do another surgery. They discovered a software glitch to a particular brand of pacemaker that could have been exploited."

Thankfully, that glitch wasn't exploited, but it put thousands of people's lives at risk by those technology designers not foreseeing this cybersecurity glitch. Anywhere devices — not just computers or phones — are used remotely or on a network, security is compromised.

Napper has only one year of the program under his belt, but he says he has already seen a lot of interest from the school's advisory board, which is made up of 75 CTO and tech leaders.

"They're lining up to get our students as interns even before we have the students ready," Napper says. "We've only finished our first freshman class."

Napper says the program is on track to have a capacity of 200 to 250 students. At a school like HBU, which has around 3,400 total students, that's a huge chunk of the school's population. Some think the program, considering the need and reception, could grow to 1,000 students.

The courses cover everything within operational and intellectual technology — device design, data science, automation, artificial intelligence — and the students are already getting their hands dirty.

"Our approach to education is learning in context. It is very hands on, but it's not hands off or hands on sake," Napper says. "There's no single class in our inventory of courses where one person stands at the front and talks the whole time. Our students carry their lab with them to class. We changed the definition of a lab. A lab is not the place you go to once a week in order to write a lab report."

This fall, the school will have its inaugural class in sophomore-level courses and a new batch of freshmen. Down the road, Napper says they'll look into creating a master's program.

Michael Tims / Houston Bapitst U

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”